Psychological and pharmacological treatments of mood and anxiety disorders during pregnancy and postpartum. Review and synthesis;Thérapeutique des troubles anxieux et dépressifs de la grossesse et du post-partum. Revue et synthèse

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 36, Issue 6, 2007, Pages 530-548

  Dayan, J ^a,b   Yoshida, K ^c  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Antidepressants; Anxiety; Breast feeding; Depression; Postpartum; Pregnancy; Psychotropic medication

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; DOSULEPIN; DOXEPIN; FLUPENTIXOL; HALOPERIDOL; IMIPRAMINE; LEVOMEPROMAZINE; LITHIUM; LOXAPAX; LOXAPINE; MAPROTILINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNCLASSIFIED DRUG; VALPROIC ACID; ZUCLOPENTHIXOL DECANOATE;

ANXIETY DISORDER; BREAST FEEDING; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG INDICATION; HUMAN; INTERVENTION STUDY; LONG TERM CARE; MOOD DISORDER; PERINATAL DEVELOPMENT; PERINATAL PERIOD; PRESCRIPTION; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; PUERPERIUM; REVIEW; RISK ASSESSMENT; SYNTHESIS; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION; CONGENITAL MALFORMATION; FEMALE; PREGNANCY; PREGNANCY COMPLICATION; PSYCHOLOGICAL ASPECT; PUERPERAL DISORDER;

ABNORMALITIES, DRUG-INDUCED; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; FEMALE; HUMANS; MOOD DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PSYCHOTROPIC DRUGS; PUERPERAL DISORDERS;

EID: 34548750954     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgyn.2007.06.004     Document Type: Review

References (126)

1. Inserm. Psychothérapie, trois approches évaluées. Expertise collective (2004), Les Éditions Inserm, Paris (553 p.)
2. Milgrom J., Negri L.M., Gemmill A.W., McNeil M., and Martin P.R. A randomized controlled trial of psychological interventions for postnatal depression. Br. J. Clin. Psychol. 44 (2005) 529-542
3. Cramer B., and Palacio-Espasa F. La pratique des psychothérapies mères-bébés (1993), PUF, Paris
4. Dimidjian S., Hollon S.D., Dobson K.S., Schmaling K.B., Kohlenberg R.J., Addis M.E., et al. Gallop. Randomized trial of behavioural activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J. Consult. Clin. Psychol. 74 4 (2006) 658-670
5. Paykel E.S. Cognitive therapy in relapse prevention in depression. Int. J. Neuropsychopharmacol. 20 (2006) 1-6
6. de Maat S.M., Dekker J., Schoevers R.A., and de Jonghe F. Relative efficacy of psychotherapy and combined therapy in the treatment of depression: A meta-analysis. Eur. Psychiatry (2006) [Epub ahead of print]
7. Burnand Y., Andreoli A., Kolatte E., Venturini A., and Rosset N. Psychodynamic psychotherapy and clomipramine in the treatment of major depression. Psychiatr. Serv. 53 5 (2002) 585-590
8. Bellino S., Zizza M., Rinaldi C., and Bogetto F. Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Can. J. Psychiatry 51 7 (2006) 453-460
9. Miklowitz D.J. A review of evidence-based psychosocial interventions for bipolar disorder. J. Clin. Psychiatry 67 Suppl. 11 (2006) 28-33
10. Cooper P.J., Murray L., Wilson A., and Romaniuk A. Controlled trial of the short- and long-term effect of psychological treatment of post-partum depression. 1. Impact on maternal mood. Br. J. Psychiatry 182 (2003) 412-419
11. Cooper P.J., Murray L., Wilson A., and Romaniuk A. Controlled trial of the short- and long-term effect of psychological treatment of post-partum depression. 2. Impact on the mother-child relationship and child outcome. Br. J. Psychiatry 182 (2003) 420-427
12. Fava G.A., Ruini C., Rafanelli C., Finos L., Conti S., and Grandi S. Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. Am. J. Psychiatry 161 10 (2004) 1872-1876
13. Barber J.P., Connolly M.B., Crits-Christoph P., Gladis L., and Siqueland L. Alliance predicts patients' outcome beyond in-treatment change in symptoms. J. Consult. Clin. Psychol. 68 6 (2000) 1027-1032
14. Baldwin D.S., Anderson I.M., Nutt D.J., Bandelow B., Bond A., Davidson J.R., et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 19 6 (2005) 567-596
15. Baldwin D.S. Evidence-based guidelines for anxiety disorders: can they improve clinical outcomes?. CNS Spectr. 11 10 Suppl 12 (2006) 34-39
16. Dennis C.L. Psychosocial and psychological interventions for prevention of postnatal depression: systematic review. BMJ 331 7507 (2005) 15
17. Austin M.P. Targeted group antenatal prevention of postnatal depression: a review. Acta Psychiatr. Scand. 107 4 (2003) 244-250
18. McElhatton P.R., Garbis H.M., Elefant E., Vial T., Bellemin B., Mastroiacovo P., et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants: a collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod. Toxicol. 10 (1996) 285-294
19. Ericson A., Kullen B., and Wilholm B.E. Delivery outcome after the use of antidepressants in early pregnancy. Eur. J. Clin. Pharmacol. 55 (1999) 503-508
20. Kallen B., and Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod. Toxicol. 21 3 (2006) 221-222
21. Hallberg P., and Sjoblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J. Clin. Psychopharmacol. 25 1 (2005) 59-73
22. Diav-Citrin O., Shechtman S., Weinbaum D., et al. Paroxetine and fluoxetine in pregnancy: a multicenter, prospective, controlled study. Reprod. Toxicol. 20 (2005) 459 [abstract]
23. Cole JA, Ng EW, Ephross SA, et al. Paroxetine in the First Trimester of Pregnancy and the Prevalence of Congenital Malformations. 22nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Lisbon. 2006; 24-27. Abstract12.
24. Malm H., Klaukka T., and Neuvonen P.J. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet. Gynecol. 106 (2005) 1289-1296
25. Kulin N.A., Pastusz-ak A., Sage S., et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors - a prospective controlled multicenter study. JAMA 279 (1998) 609-610
26. Simon G.E., Cunninghan M.L., and Davis R.L. Outcomes of prenatal antidepressant exposure. Am. J. Psychiatry 159 (2002) 2055-2061
27. Hendrick V., Smith L.M., Suri R., et al. Birth outcomes after prenatal exposure to antidepressant medication. Am. J. Obstet. Gynecol. 188 (2003) 812-815
28. Wogelius P., Norgaard M., Munk E.M., et al. Maternal use of selective serotonin reuptake inhibitors and risk of adverse pregnancy outcomes. Pharmacoepidemiol. Drug Safe Abstract 14 143 (2005) S72-S73
29. Alwan S., Reefhuis J., Rasmussen S., et al. Maternal use of selective serotonin re-uptake inhibitors and risk for birth defects. Birth Defects Res. A Clin. Mol. Teratol. 73 (2005) 291
30. Kallen B.A., and Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol (2007) [Epub ahead of print]
31. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., Werler M.M., Louik C., and Jones K.L. A selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med. 354 6 (2006) 579-587
32. Yaris F., Kadioglu M., Kesim M., Ulku C., Yaris E., Kalyoncu N.I., et al. Newer antidepressants in pregnancy: prospective outcome of a case series. Reprod. Toxicol. 19 2 (2004) 235-238
33. Djulus J., Koren G., Einarson T.R., Wilton L., Shakir S., Diav-Citrin O., et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J. Clin. Psychiatry 67 8 (2006) 1280-1284
34. Webster P.A. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 2 7824 (1973) 318-319
35. Eggermont E. Withdrawal symptoms in neonates associated with maternal imipramine therapy. Lancet 2 7830 (1973) 680
36. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch. Pediatr. Adolesc. Med. 158 4 (2004) 312-316
37. Oberlander T.F., Warburton W., Misri S., Aghajanian J., and Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch. Gen. Psychiatry 63 8 (2006) 898-906
38. Sanz E.J., De-las-Cuevas C., Kiuru A., Bate A., and Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 365 9458 (2005) 482-487
39. Chambers C.D., Johnson K.A., Dick L.M., Felix R.J., and Jones K.L. Birth outcomes in pregnant women taking fluoxetine. N. Engl. J. Med. 335 14 (1996) 1010-1015
40. Costei A.M., Kozer E., Ho T., Ito S., and Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch. Pediatr. Adolesc. Med. 156 11 (2002) 1129-1132
41. Oberlander T.F., Misri S., Fitzgerald C.E., Kostaras X., Rurak D., and Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J. Clin. Psychiatry 65 (2004) 230-237
42. Hendrick V., Smith L.M., Suri R., Hwang S., Haynes D., and Altshuler L. Birth outcomes after prenatal exposure to antidepressant medication. Am. J. Obstet. Gynecol. 188 3 (2003) 812-815
43. McElhatton P.R., Garbis H.M., Elefant E., Vial T., Bellemin B., Mastroiacovo P., et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants: a collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod. Toxicol. 10 (1996) 285-294
44. Sanz E.J., De-las-Cuevas C., Kiuru A., Bate A., and Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 365 (2005) 482-487
45. Morag I., Batash D., Keidar R., Bulkowstein M., and Heyman E.J. Paroxetine use throughout pregnancy: does it pose any risk to the neonate?. J. Toxicol Clin. Toxicol 42 1 (2004) 97-100
46. Misri S., Kim J., Riggs K.W., and Kostaras X. Paroxetine levels in postpartum depressed women, breast milk, and infant serum. J. Clin. Psychiatry 61 (2000) 828-832
47. Laine K., Heikkinen T., Ekblad U., and Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch. Gen. Psychiatry 60 7 (2003) 720-726
48. Misri S., and Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int. J. Psychiatry Med. 21 (1991) 157-171
49. Misri S., Reebye P., Kendrick K., Carter D., Ryan D., Grunau R.E., et al. Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am. J. Psychiatry 163 6 (2006) 1026-1032
50. Nulman I., Rovet J., Stewart D.E., Wolpin J., Gardner H.A., Theis J.G., et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N. Engl. J. Med. 336 4 (1997) 258-262
51. Nulman I., Rovet J., Stewart D.E., Wolpin J., Pace-Asciak P., Shuhaiber S., et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am. J. Psychiatry 159 11 (2002) 1889-1895
52. Casper R.C., Fleisher B.E., Lee-Ancajas J.C., Gilles A., Gaylor E., DeBattista A., et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J. Pediatr. 142 4 (2003) 402-408
53. Gentile S. SSRIs in pregnancy and lactation: emphasis on neurodevelopmental outcome. CNS Drugs 19 7 (2005) 623-633
54. Morrison J.L., Riggs K.W., and Rurak D.W. Fluoxetine during pregnancy: impact on fetal development. Reprod. Fertil. Dev. 17 6 (2005) 641-650
55. Zeskind P.S., and Stephens L.E. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn. Neurobehavior. Pediatrics 113 2 (2004) 368-375
56. Weissman M.M., Pilowsky D.J., Wickramaratne P.J., Talati A., Wisniewski S.R., Fava M., et al. Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA 295 12 (2006) 1389-1398 [Erratum in. JAMA 2006;296(10):1234]
57. Cohen L.S., Friedman J.M., Jefferson J.W., Johnson E.M., and Weiner M.L. A reevaluation of risk of in utero exposure to lithium. JAMA 271 (1994) 146-150
58. Jacobson S.J., Jones K., Johnson K., Ceolin L., Kauer P., Sahn K., et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 339 (1992) 530-533
59. Schou M., and Amdisen A. Lithium and pregnancy: lithium ingestion by children breast-fed by women on lithium treatment. BMJ 2 (1973) 138
60. Newport D.J., Viguera A.C., Beach A.J., Ritchie J.C., Cohen L.S., and Stowe Z.N. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am. J. Psychiatry 162 11 (2005) 2162-2170
61. Nars P.W., and Girard J. Lithium carbonate intake during pregnancy leading to large goiter in a premature infant. Am. J. Dis. Child. 131 8 (1977) 924-925
62. Schou M. What happened later to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr. Scand. 54 (1976) 193-197
63. Omtzigt J. The disposition of valproate and its metabolites in the late first trimester and early second trimester of pregnancy in maternal serum, urine, and amniotic fluid: effect of dose, comedication, and the presence of spina bifida. Eur. J. Clin. Pharmacol. 43 (1992) 381-388
64. Lindhout D., and Omtzigt J.G. Teratogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age. Epilepsia 35 (1994) S19-S28
65. Omtzigt J. Prenatal diagnosis of spina bifida aperta after first-trimester valproate exposure. Prenat. Diagn. 12 (1992) 893-897
66. Kennedy D., and Koren G. Valproic acid use in psychiatry: issues in treating women of reproductive age. J. Psychiatry Neurosci. 23 (1998) 223-228
67. Holmes L.B., Harvey E.A., Coull B.A., Huntington K.B., Khoshbin S., Hayes A.M., et al. Teratogenicity of anticonvulsant drugs. N Engl J Med 334 (2002) 1132-1138
68. Jones K.L., Lacro R.V., Johnson K.A., and Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N. Engl. J. Med. 320 (1989) 1661-1666
69. Rosa F.W. Spina bifida in infants of women treated with carbamazepine during pregnancy. N. Engl. J. Med. 324 (1991) 674-677
70. Holmes L.B., Wyszynski D.F., Baldwin E.J., et al. Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy. Birth Defects Res. Part A Clin. Mol. Teratol. 76 (2006) 318
71. Scolnick D. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 271 (1994) 767-770
72. DiLiberti J., Farndon P., Dennis N., and Curry C. The fetal valproate syndrome. Am. J. Med. Genet. 19 (1984) 473-481
73. Dean J.C., Hailey H., Moore S.J., Lloyd D.J., Turnpenny P.D., and Little J. Long-term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J. Med. Genet. 39 4 (2002) 251-259
74. Altshuler L.L., Cohen L.S., Szuba M.P., Burt V.K., Gitlin M., and Mintz J. Pharmacologic management of psychiatric illness in pregnancy: dilemmas and guidelines. Am. J. Psychiatry 153 (1996) 592-606
75. Kopelman A.E., McCulllar F.W., and Heggeness L. Limb malformations following maternal use of haloperidol. JAMA 231 (1975) 62-64
76. Van Waes A., and Van de Velde E. Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum. J. Clin. Pharmacol. 9 (1969) 224-237
77. In: Briggs G.G., Freeman R.K., and Yaffe S.J. (Eds). Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk (2000), Radcliffe Medical Press, Oxon 498-499 (5th ed)
78. McKenna K., Koren G., Tetelbaum M., Wilton L., Shakir S., Diav-Citrin O., et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J. Clin. Psychiatry 66 4 (2005) 444-449
79. Waldman M.D., and Safferman A.Z. Pregnancy and clozapine. Am. J. Psychiatry 150 (1993) 168-169
80. Barnas C., Bergant A., Hummer M., Saria A., and Fleischhacker W.W. Clozapine concentrations in maternal and fetal plasma, amniotic fluid and breast milk. Am. J. Psychiatry 151 (1994) 945
81. Dickson R.A., and Hogg L. Pregnancy of a patient treated with clozapine. Psychiatr. Serv. 49 (1998) 1081-1083
82. DiMichele V., Ramenghi L.A., and Sabationo G. Clozapine and clorazepam administration in pregnancy. Eur. Psychiatry 11 (1996) 214
83. Stoner S.C., Sommi Jr. R.W., Marken P.A., Anya I., and Vaughn J. Clozapine use in two full term pregnancies. J. Clin. Psychiatry 58 (1997) 364-365
84. Gupta N., and Grover S. Safety of clozapine in two successive pregnancies. Can. J. Psychiatry 49 (2004) 863
85. Grover S., Avasthi A., and Sharma Y. Psychotropics in pregnancy: weighing the risks. Indian J. Med. Res. 123 4 (2006) 497-512
86. Goldstein D.J., Corbin L.A., and Fung M.C. Olanzapine-exposed pregnancies and lactation: early experience. J. Clin. Psychopharmacol. 20 4 (2000) 399-403
87. Auerbach J.G., Hans S.L., Marcus J., and Maeir S. Maternal psychotropic medication and neonatal behaviour. Neurotoxicol. Teratol. 14 6 (1992) 399-406
88. Trixler M., Gati A., Fekete S., and Tenyi T. Use of antipsychotics in the management of schizophrenia during pregnancy. Drugs 65 9 (2005) 1193-1206
89. Baldwin D.S., Anderson I.M., Nutt D.J., Bandelow B., Bond A., Davidson J.R., et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 19 6 (2005) 567-596
90. Aarskog D. Association between maternal intake of diazepam and oral clefts. Lancet 2 (1975) 921 (letter)
91. McElhatton P.R. The effects of benzodiazepine use during pregnancy and lactation. Reprod. Toxicol. 8 (1994) 461-475
92. Iqual M.M., Sobhan T., and Ryals T. Effects of commonly used benzodiazepines on the foetus, the neonate and the nursing infant. Psychiatr. Ser. 53 (2002) 39-49
93. Dolovich L.R., Addis A., Vaillancourt J.M., Power J.D., Koren G., and Einarson T.R. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. Br. Med. J. (Clin. Res. Ed.) 317 (1998) 839-843
94. Briggs G., Freeman R., and Yaffe S. Drugs in Pregnancy and Lactation (2002), Lippincott Williams & Wilkins, Philadelphia
95. Weinstock L. Obstetrical and neonatal outcome following clonazepam use during pregnancy: a case series. Psychother. Psychosom. 70 (1996) 158-162
96. Laegreid L., Hagberg G., and Lundberg A. Neurodevelopment in late infancy after prenatal exposure to benzodiazepines- a prospective study. Neuropediatrics 23 (1992) 60-67
97. Bergman U., Rosa F.W., Baum C., Wiholm B.E., and Faich G.A. Effects of exposure to benzodiazepine during fetal life. Lancet 340 (1992) 694-696
98. Hale T.W. Medications and mothers' milk: 1999-2000. 8th ed (1999), Pharmasoft Medical, Amarillo
99. Yoshida K., Smith B., and Kumar R. Psychotropic drugs in mothers' milk: a comprehensive review of assay methods, pharmacokinetics and of safety of breast-feeding. J. Psychopharmacol. 13 1 (1999) 64-80
100. Weissman A.M., Levy B.T., Hartz A.J., Bentler S., Donohue M., Ellingrod V.L., et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am. J. Psychiatry 161 (2004) 1066-1078
101. Rubin E.T., Lee A., and Ito S. When breast-feeding mothers need CNS-acting drugs. Can. J. Clin. Pharmacol. 11 2 (2004) 257-266
102. Matheson I., Pande H., and Altersen A.R. Respiratory depression caused by N-desmethyldoxepin in breast milk. Lancet 2 (1985) 1124 (letter)
103. Buist A., and Janson H. Effect of exposure to dothiepin and northiaden in breast milk on child development. Br. J. Psychiatry 167 3 (1995) 370-373
104. Yoshida K., Smith B., Craggs M., and Kumar R.C. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. J. Affect. Disord. 43 3 (1997) 225-237
105. Berle J.O., Steen V.M., Aamo T.O., Breilid H., Zahlsen K., and Spigset O. Breast-feeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. J. Clin. Psychiatry 65 9 (2004) 1228-1234
106. Schmidt K., Olesen O.V., and Jensen P.N. Citalopram and breast-feeding: serum concentration and side effects in the infant. Biol. Psychiatry 47 2 (2000) 164-165
107. Stowe Z.N., Owens M.J., Landry J.C., Kilts C.D., Ely T., Llewellyn A., et al. Sertraline and desmethylsertraline in human breast milk and nursing infants. Am. J. Psychiatry 154 9 (1997) 1255-1260
108. Schou M. Treating recurrent affective disorders during and after pregnancy. What can be taken safely?. Drug Saf. 18 2 (1998) 143-152
109. Weinstein M.R. Lithium treatment of women during pregnancy and in the post-delivery period. In: Johnson F.N. (Ed). Handbook of lithium therapy (1980), University Park Press, Baltimore 421-429
110. Tunnessen W.W., and Hertz C.G. Toxic effects of lithium in newborn infants. A commentary. J. Pediatr. 81 4 (1972) 804-807
111. Schou M., Amdisen A., and Steenstrup O.R. Lithium and pregnancy. II. Hazards to women given lithium during pregnancy and delivery. BMJ 2 5859 (1973) 137-138
112. Sykes P.A., Quarries J., and Alexander F.W. Lithium carbonate and breast-feeding. BMJ 27 (1976) 131
113. Moretti M.E., Koren G., Verjee Z., and Ito S. Monitoring lithium in breast milk: an individualized approach for breast-feeding mothers. Ther. Drug Monit. 25 3 (2003) 364-366
114. Linden S., and Rich C.L. The use of lithium during pregnancy and lactation. Clin. Psychiatry 44 10 (1983) 358-361
115. Stewart D.E. Prophylactic lithium in postpartum affective psychosis. J. Nerv. Ment. Dis. 176 (1988) 485-489
116. Llewellyn A., Stowe Z.N., and Strader J.R. The use of litium and management of women with bipolar disorder during pregnancy and lactation. J. Clin. Psychiatry 59 (1998) 57-64
117. Wisner K.L., and Perel J.M. Serum levels of valproate and carbamazepine in breast-feeding mother-infant pairs. J. Clin. Psychopharmacol. 18 2 (1998) 167-169
118. Dodd S., and Berk M. The pharmacology of bipolar disorder during pregnancy and breast-feeding. Expert Opin. Drug Saf. 3 3 (2004) 221-229
119. Frey B., Braegger C.P., and Ghelfi D. Neonatal cholestatic hepatitis from carbamazepine exposure during pregnancy and breast-feeding. Ann. Pharmacother. 36 4 (2002) 644-647
120. Liporace J., Kao A., and D'Abreu A. Concerns regarding lamotrigine and breast-feeding. Epilepsy Behav. 5 1 (2004) 102-105
121. Gentile S. Clinical utilization of atypical antipsychotics in pregnancy and lactation. Ann. Pharmacother. 38 7-8 (2004) 1265-1271
122. Erkkola R., and Kanto J. Diazepam and breast-feeding. Lancet 3 (1972) 1235-1236
123. Birnbaum C.S., Cohen L.S., Bailey J.W., Grush L.R., Robertson L.M., and Stowe Z.N. Serum concentrations of antidepressants and benzodiazepines in nursing infants: A case series. Pediatrics 104 (1999) 11
124. McElhatton P.R. The effects of benzodiazepine use during pregnancy and lactation. Reprod. Toxicol. 8 6 (1994) 461-475
125. Grunze H. Reevaluating therapies for bipolar depression. J. Clin. Psychiatry 66 Suppl 5 (2005) 17-25
126. Maletzky B.M. The first-line use of electroconvulsive therapy in major affective disorders. J. ECT 20 2 (2004) 112-117